［1］Au HJ,Eiermann W,Robert NJ,et al.Health-related quality of life with adjuvant docetaxel- and trastuzumab-based regimens in patients with node-positive and high-risk node-negative,HER2-positive early breast cancer:Results from the BCIRG 006 study［J］.Oncologist,2013,18 (7):812-818.
［2］Perez EA,Press MF,Dueck AC,et al.Immunohistochemistry and fluorescence in situ hybridization assessment of HER2 in clinical trials of adjuvant therapy for breast cancer (NCCTG N9831,BCIRG 006,and BCIRG 005)［J］.Breast Cancer Res Treat,2013,138(1):99-108.
［3］Perez EA,Romond EH,Suman VJ,et al.Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer:Joint analysis of data from NCCTG N9831 and NSABP B-31［J］.J Clin Oncol,2011,29(25):3366-3373.
［4］Untch M,Gelber RD,Jackisch C,et al.Estimating the magnitude of trastuzumab effects within patient subgroups in the HERA trial［J］.Ann Oncol,2008,19(6):1090-1096.
［5］Purmonen TT,Pankalainen E,Turunen JH,et al.Short-course adjuvant trastuzumab therapy in early stage breast cancer in Finland:Cost-effectiveness and value of information analysis based on the 5-year follow-up results of the fin her trial［J］.Acta Oncologica,2011,50(3):344-352.
［6］Gianni L,Eiermann W,Semiglazov V,et al.Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH):Follow-up of a randomised controlled superiority trial with a parallel HER2-negative cohort［J］.Lancet Oncol,2014,15 (6):640-647.
［7］Huszno J,Badora A,Nowara E.The influence of steroid receptor status on the cardiotoxicity risk in HER2-positive breast cancer patients receiving trastuzumab［J］.Archives of Med Sci,2015,11(2):371-377.
［8］Mendes D,Alves C,Afonso N,et al.The benefit of HER2-targeted therapies on overall survival of patients with metastatic HER2-positive breast cancer-a systematic review［J］.Breast Cancer Res,2015,17:140.
［9］Swain SM,Baselga J,Miles D,et al.Incidence of central nervous system metastases in patients with HER2-positive metastatic breast cancer treated with pertuzumab,trastuzumab,and docetaxel:Results from the randomized phase III study CLEOPATRA［J］.Ann Oncol,2014,25(6):1116-1121.
［10］Carey LA,Berry DA,Cirrincione CT,et al.Molecular heterogeneity and response to neoadjuvant human epidermal growth factor receptor 2 targeting in CALGB 40601,a randomized phase III trial of paclitaxel plus trastuzumab with or without lapatinib［J］.J Clin Oncol,2016,34(6):542.
［11］Sendur MA,Aksoy S,Altundag K.Pertuzumab-induced cardiotoxicity:Safety compared with trastuzumab［J］.Future Oncol,2015,11(1):13.
［12］Blackwell KL,Burstein HJ,Storniolo AM,et al.Overall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer:Final results from the EGF104900 Study［J］.J Clin Oncol,2012,30(21):2585-2592.
［13］Robidoux A,Tang G,Rastogi P,et al.Lapatinib as a component of neoadjuvant therapy for HER2-positive operable breast cancer (NSABP protocol B-41):An open-label,randomised phase 3 trial［J］.Lancet Oncol,2013,14(12):1183-1192.
［14］Verma S,Miles D,Gianni L,et al.trastuzumab emtansine for HER2-positive advanced breast cancer［J］.New Eng J Med,2012,367(19):1783-1791.
［15］Krop IE,Lin NU,Blackwell K,et al.trastuzumab emtansine (T-DM1) versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer and central nervous system metastases:A retrospective,exploratory analysis in EMILIA［J］? Ann Oncol,2015,26(1):113-119.
［16］Krop IE,Kim SB,González-Martín A,et al.trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA):A randomised,open-label,phase 3 trial［J］.Lancet Oncol,2014,15(7):689.
［17］Ryden L,Heibert Arnlind M,Vitols S,et al.Aromatase inhibitors alone or sequentially combined with tamoxifen in postmenopausal early breast cancer compared with tamoxifen or placebo - Meta-analyses on efficacy and adverse events based on randomized clinical trials［J］.Breast,2016,26:106-114.
［18］Mayer IA,Abramson VG,Formisano L,et al.A Phase Ib study of alpelisib (BYL719),a PI3Kα-specific lnhibitor,with letrozole in ER+/HER2-metastatic breast cancer［J］.Clin Cancer Res,2017,23(1):26.
［19］André F,O' Regan R,Ozguroglu M,et al.Everolimus for women with trastuzumab-resistant,HER2-positive,advanced breast cancer (BOLERO-3)［J］.Lancet Oncol,2015,15(6):580-591.
［20］Baselga J,Segalla JG,Roche H,et al.Sorafenib in combination with capecitabine:An oral regimen for patients with HER2-negative locally advanced or metastatic breast cancer［J］.J Clinical Oncol,2012,30(13):1484-1491.
［21］Garon EB,Cao D,Alexandris E,et al.A randomized,double-blind,phase III study of docetaxel and ramucirumab versus docetaxel and placebo in the treatment of stage IV non-small-cell lung cancer after disease progression after 1 previous platinum-based therapy (REVEL):Treatment rationale and study design［J］.Clin Lung Cancer,2012,13(6):505-509.
［22］Wilke H,Muro K,Cutsem EV,et al.Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW):A double-blind,randomised phase 3 trial［J］.Lancet Oncol,2014,15(11):1224-1235.
［23］Mackey JR,Ramos-Vazquez M,Lipatov O,et al.Primary results of ROSE/TRIO-12,a randomized placebo-controlled phase III trial evaluating the addition of ramucirumab to first-line docetaxel chemotherapy in metastatic breast cancer［J］.J Clin Oncol,2015,33(2):141-148.
［24］Travis CG,Litton JK,Arrington K,et al.Results of a phase Ib trial of combination immunotherapy with a CD8+ T cell eliciting vaccine and trastuzumab in breast cancer patients［J］.Ann Surg Oncol,2017,3(12):1-7.
［25］Ozkavruk Eliyatkin N,Aktas S,Ozgur H,et al.The role of p95HER2 in trastuzumab resistance in breast cancer［J］.J BUON,2016,21 (2):382-389.
［26］Costa R,Shah AN,Santa-Maria CA,et al.Targeting epidermal growth factor receptor in triple negative breast cancer:New discoveries and practical insights for drug development［J］.Cancer Treatment Reviews,2017,53:111.
［27］Baselga J,Gómez P,Greil R,et al.Randomized phase II study of the anti-epidermal growth factor receptor monoclonal antibody cetuximab with cisplatin versus cisplatin alone in patients with metastatic triple-negative breast cancer［J］.J Clin Oncol,2013,31(20):2586-2592.
［28］Carey LA,Rugo HS,Marcom PK,et al.TBCRC 001:Randomized phase II study of cetuximab in combination with carboplatin in stage IV triple-negative breast cancer［J］.J Clin Oncol,2012,30(21):2615-2623.
［29］O' Shaughnessy J,Osborne C,Pippen JE,et al.Iniparib plus chemotherapy in metastatic triple-negative breast cancer［J］.New Eng J Med,2011,364(3):205-214.
［30］O' Shaughnessy J,Schwartzberg L,Danso MA,et al.Phase III study of iniparib plus gemcitabine and carboplatin versus gemcitabine and carboplatin in patients with metastatic triple-negative breast cancer［J］.J Clin Oncol,2014,32(34):3840.
［31］Salazar LG,Lu H,Reichow JL,et al.Topical imiquimod plus nab-paclitaxel for breast cancer cutaneous metastases:A phase 2 clinical trial［J］.JAMA Oncology,2017,3(7):969-973.
［32］Finn RS,Crown JP,Lang I,et al.The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive,HER2-negative,advanced breast cancer (PALOMA-1/TRIO-18):A randomised phase 2 study［J］.Lancet Oncol,2015,16(1):25-35.
［33］Romero D.Breast cancer:PALOMA-2-hope beyond the threshold［J］.Nature Reviews Clinical Oncology,2017,14(1):1.